Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Revenue (2016 - 2025)

Historic Revenue for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $200000.0.

  • Northwest Biotherapeutics' Revenue fell 4397.76% to $200000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $937000.0, marking a year-over-year decrease of 4129.07%. This contributed to the annual value of $1.4 million for FY2024, which is 2846.79% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its Revenue stood at $200000.0 for Q3 2025, which was down 4397.76% from $131000.0 recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Revenue ranged from a high of $880000.0 in Q1 2023 and a low of $131000.0 during Q2 2025
  • Moreover, its 5-year median value for Revenue was $366000.0 (2024), whereas its average is $372666.7.
  • Its Revenue has fluctuated over the past 5 years, first soared by 2070000.0% in 2021, then tumbled by 7431.37% in 2025.
  • Northwest Biotherapeutics' Revenue (Quarter) stood at $350000.0 in 2021, then surged by 70.57% to $597000.0 in 2022, then decreased by 25.46% to $445000.0 in 2023, then plummeted by 48.09% to $231000.0 in 2024, then dropped by 13.42% to $200000.0 in 2025.
  • Its Revenue stands at $200000.0 for Q3 2025, versus $131000.0 for Q2 2025 and $375000.0 for Q1 2025.